Nabi Biopharmaceuticals

What Nabi Biopharmaceuticals does

Nabi Biopharmaceuticals is a for-profit biopharmaceutical company historically focused on developing preventive measures and treatments for diseases, headquartered in Rockville, Maryland, and originally founded in 1967. The company previously traded on NASDAQ under the ticker symbol NABI but is now delisted, and the current input indicates a contracted headcount of 1-10 employees with no active management team, product portfolio, customer base, pricing model, or revenue stream documented in the supplied material. The corporate web property at nabi.com currently resolves to a Markmonitor domain-inquiry landing page indicating the domain may be for sale, and no clinical pipeline, regulatory filings, partnerships, or technology stack are present in the input. The only dated capital-formation event on record is a single funding round of $10,000,000 on 2009-09-29 with unspecified investors and lead, and the broader ownership, subsidiary, and operating-geography fields are empty.

Taken together, the available evidence describes Nabi Biopharmaceuticals as either a dormant shell or a minimally staffed residual entity rather than an operating biopharmaceutical business. There is no disclosed go-to-market motion, distribution channel, revenue model, or product surface from which to derive current commercial activity. Strategic value, if any, would reside in legacy intellectual property, biologic assets, or trademarks not enumerated in the current dataset, but none of these are visible in the input and therefore cannot be characterized with confidence. The data gap is significant: the input does not confirm whether the entity is in active wind-down, has been acquired and is operating under a different banner, or retains any latent licensable assets, so any investment thesis should be built around confirmation of those unknowns before valuation.

Name

Nabi Biopharmaceuticals

Website

https://nabi.com

Company type

Private

Founded year

1967

Headcount range

1–10 employees

Short description

Nabi Biopharmaceuticals was a Rockville, Maryland-based biopharmaceutical company developing preventive measures and treatments for diseases; it is now delisted from NASDAQ, operates with 1-10 employees, and shows no active products, customers, or revenue in the input data.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Biopharmaceutical development
• Disease prevention therapies
• Vaccine development
• Therapeutic treatments
• Pharmaceutical research

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Nabi Biopharmaceuticals develops preventive measures and treatments for diseases. The company is a biopharmaceutical firm focused on creating biological products for disease prevention and therapeutic intervention. Its historical operations have centered on pharmaceutical R&D and product commercialization.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Direct peers

• Bavarian Nordic: Vaccine-focused biotechnology company specializing in infectious disease and biodefense, directly comparable to Nabi's historical vaccine franchise.
• Dynavax Technologies: Specialty vaccine developer with adjuvanted and immune-modulating products targeting infectious disease, comparable to Nabi's vaccine and immune-based product strategy.
• VBI Vaccines: Smaller specialty vaccine developer focused on infectious disease and immuno-oncology, with a similar scale profile and pipeline orientation to Nabi's historical scope.
• Emergent BioSolutions: Specialty vaccines and antibody therapeutics developer historically focused on infectious disease and biodefense, directly overlapping Nabi's historical portfolio of vaccines and immune globulins.
• Novavax: Vaccine-focused biotechnology company developing immunogenic products for infectious diseases, sharing Nabi's historical focus on prophylactic biologics.

Broad incumbents

• Merck & Co. Large pharmaceutical incumbent with a substantial vaccines and infectious disease franchise, operating as a broad competitor to specialty players like Nabi across overlapping indications.
• GSK: Global biopharma incumbent with one of the largest vaccine portfolios, competing directly with smaller specialty vaccine developers in infectious disease.
• Sanofi Pasteur: The vaccines division of Sanofi, a global incumbent offering an extensive infectious disease vaccine portfolio that overlaps with the therapeutic categories Nabi historically targeted.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

• Xx.com/nabitablet
• Facebookfacebook.com/nabitablet

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nabi Biopharmaceuticals